Pubmed, gene database PPD, purified protein derivate, is in the tuberculin skin test (TST) and has a substantial antigenic overlap with BCG [1] [2] [3] . ESAT-6, Rv2660c and RV1196 are in novel TB vaccines currently in clinical testing [4] . ESAT-6 and CFP10 are two of the antigens used in QFT [1, 5, 6] . ESAT-6, CFP10, Rv3614, Rv3865, Rv3872 and Rv3849 are region of difference 1 (RD1) antigens and all but Rv3872 are part of the ESAT-6 antigen secretion system operon (ESX-1) [6] [7] [8] [9] [10] [11] . Rv3872 and Rv1196 are part of the PE and PPE families, which constitute 10% of the Mtb genome [10] [11] [12] [13] [14] . Rv0203 is proposed to be a secreted heme transporter that mediate Mtb heme iron uptake [15, 16] . Rv2660c, Rv1284, Rv2659, Rv2031, Rv2244 are all induced by either bacterial hypoxia or starvation, are a part of the enduring hypoxia response or dormancy regulon antigens (DosR) [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . 
RESULTS
) Subsequent TB: tuberculosis disease notified through the National TB register at any point from study enrolment to end of follow-up. QFT: QuantiFERON®-TB Gold test TST: Tuberculin skin test Rv1196 and Rv2659 response levels were generated from the maximum response of the included pools, which partly explains higher values for these two antigens compared to other antigens. The median IFNy level was 7.4 pg/ml. 80% the IFNy levels were less than ¾ of the cut-point level. When not considering Rv1196 and Rv2659, 97% of the IFNy levels were less that ¾ of the cutpoint level. HRs relate to the risk of TB during follow-up. . A substantial CFP10 increase was observed for 21 participants had during follow-up, four progress to subsequent TB. The time from CFP10 increase to TB was 7, 10, 10 and 10 months for four participants while no TB was observed in 17 participants until end of follow-up
